ArticleCancer genetics2015
ARID1A and TERT promoter mutations in dedifferentiated meningioma.
Article in Cancer genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.Neurosurgical review · 2020Pooled it
- The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.Journal of neuro-oncology · 2019Pooled it
- Article
- Advances in molecular and genetic profiling of meningiomas for improved diagnosis, prognosis, and targeted therapy.Frontiers in oncology · 2026Review
- Evolving Treatment Paradigms of Meningiomas; a Precision Medicine Perspective.Current neurology and neuroscience reports · 2025Review
- cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.Neuro-oncology · 2025Review
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- Article
- The role of radiation therapy and systemic treatments in meningioma: The present and the future.Cancer medicine · 2023Review
- ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.Journal of cancer research and clinical oncology · 2023Article
- The roles of the SWI/SNF complex in cancer.Cancer cytopathology · 2023Article
- Meningioma Grading beyond Histopathology: Relevance of Epigenetic and Genetic Features to Predict Clinical Outcome.Cancers · 2023Review
- Landscape of chromatin remodeling gene alterations in endometrial carcinoma.Gynecologic oncology · 2023Article
- Epigenetic Regulation in Primary CNS Tumors: An Opportunity to Bridge Old and New WHO Classifications.Cancers · 2023Review
- Genomic Landscape of Meningiomas.Advances in experimental medicine and biology · 2023Article
- Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.Acta neurochirurgica · 2022Article
- Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.Neurologia medico-chirurgica · 2022Review
- A molecularly integrated grade for meningioma.Neuro-oncology · 2022Article
- ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications.Diagnostic pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Unlike patients with World Health Organization (WHO) grade I meningiomas, which are considered benign, patients with WHO grade III meningiomas have very high mortality rates. The principles underlying tumor progression in meningioma are largely unknown, yet a detailed understanding of these mechanisms will be required for effective management of patients with these high grade lethal tumors. We present a case of an intraventricular meningioma that at first presentation displayed remarkable morphologic heterogeneity-composed of distinct regions independently fulfilling histopathologic criteria for WHO grade I, II, and III designations. The lowest grade regions had classic meningothelial features, while the highest grade regions were markedly dedifferentiated. Whereas progression in meningiomas is generally observed during recurrence following radiation and systemic medical therapies, the current case offers us a snapshot of histologic progression and intratumoral heterogeneity in a native pretreatment context. Using whole exome sequencing and high resolution array-based comparative genomic hybridization, we observed marked genetic heterogeneity between the various areas. Notably, in the higher grade regions we found increased aneuploidy with progressive loss of heterozygosity, the emergence of mutations in the TERT promoter, and compromise of ARID1A. These findings provide new insights into intratumoral heterogeneity in the evolution of malignant phenotypes in anaplastic meningiomas and potential pathways of malignant progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.